Vaka 16
Özet
Diffüz düşük gradeli astrositomlar, genç erişkinlerde sık görülen, infiltratif büyüme paternine sahip yavaş progresyon gösteren gliomlardır. MRG’de T2 hiperintens, T1 hipointens olup genellikle belirgin kontrast tutulumu göstermezler. Tedavi; takip, cerrahi rezeksiyon ve gerektiğinde adjuvan tedavileri içerir.
Referanslar
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-1
Daniel J Brat, Roel G W Verhaak, Kenneth D Aldape, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine 2015;372(26):2481–2498. doi: 10.1056/NEJMoa1402121
Medscape.Low-Grade Astrocytoma: Background, Pathophysiology, Epidemiology. Available from: https://emedicine.medscape.com/article/1156429-overview?form=fpf(Accessed 2025 Sep 18).
Salzman KL. Diffuse Low Grade Astrositom. Bennet NI (Ed). Diagnostic Imaging Brain. Philadelphia: Elsevier; 2021. p. 458–462.
Juratli TA, Tummala SS, Riedl A, et al. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. Journal of Neuro-Oncology .2019;141:327-335. doi:org/10.1007/s11060-018-03034-6
Bisdas S, Kirkpatrick M, Giglio P,et al. Cerebral Blood Volume Measurements by Perfusion-Weighted MR Imaging in Gliomas: Ready for Prime Time in Predicting Short-Term Outcome and Recurrent Disease? American Journal of Neuroradiology .2009;30(4):681–8.doi: 10.3174/ajnr.A1465
Barbato MI, Barone AK, Aungst SL, et al. FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery. Clinical Cancer Research.2025;31(21):4412-4418.doi: 10.1158/1078-0432.CCR-25-1333
